benzyl N-[(4-{[(tert-butoxy)carbonyl]amino}phenyl)methyl]carbamate | 630125-51-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl N-[(4-{[(tert-butoxy)carbonyl]amino}phenyl)methyl]carbamate
• 英文别名: [4-(benzyloxycarbonylamino-methyl)phenyl]-carbamic acid tert-butyl ester；benzyl N-[[4-[(2-methylpropan-2-yl)oxycarbonylamino]phenyl]methyl]carbamate
• CAS: 630125-51-8
• 化学式: C₂₀H₂₄N₂O₄
• 分子量: 356.422
• InChiKey: AMMKFVUYUSWJKZ-UHFFFAOYSA-N

物化性质

• 熔点：
  130 °C
• 沸点：
  488.2±45.0 °C(Predicted)
• 密度：
  1.185±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  26
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  76.7
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  benzyl N-[(4-{[(tert-butoxy)carbonyl]amino}phenyl)methyl]carbamate 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 tert-butyl N-[4-(isothiocyanatomethyl)phenyl]carbamate
  参考文献：
  名称：

  Analysis of structure–activity relationships for the ‘B-region’ of N-(4-t-butylbenzyl)-N′-[4-(methylsulfonylamino)benzyl]-thiourea analogues as TRPV1 antagonists

  摘要：

  The structure-activity relationships for the 'B-region' of N-(4-t-butylbenzyl)-N '-[4-(methylsulfonylamino)benzyl]thiourea analogues have been investigated as TRPV1 receptor antagonists. A docking model of potent antagonist 2 with the sensor region of TRPV1 is proposed. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.06.006
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 溶剂黄146 、 三乙胺 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 水 为溶剂， 反应 2.0h， 生成 benzyl N-[(4-{[(tert-butoxy)carbonyl]amino}phenyl)methyl]carbamate
  参考文献：
  名称：

  [EN] FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING)
  [FR] COMPOSÉS HÉTÉROCYCLIQUES FONCTIONNALISÉS UTILISÉS EN TANT QUE MODULATEURS DU STIMULATEUR DES GÈNES DE L'INTERFÉRON (STING)

  摘要：

  这项发明涉及化合物-连接物构造和化合物的抗体药物偶联物，其化学式为(I)，可用作STING（干扰素基因刺激剂）调节剂。

  公开号：

  WO2021116446A1

文献信息

• Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
  申请人：Floersheimer Andreas

  公开号：US20060128734A1

  公开（公告）日：2006-06-15

  The invention relates to the use of diaryl urea derivatives in the treatment of protein kinase dependent diseases or for the manufacture of pharmaceutical compositions for use in the treatment of said diseases, methods of use of diaryl urea derivatives in the treatment of said diseases, pharmaceutical preparations comprising diaryl urea derivatives for the treatment of said diseases, diaryl urea derivatives for use in the treatment of said diseases, novel diaryl urea derivatives, pharmaceutical preparations comprising these novel diaryl urea derivatives, processes for the manufacture of the novel diaryl urea derivatives, the use or methods of use of the novel diaryl urea derivatives as mentioned above, and/or these novel diaryl urea derivatives for use in the treatment of the animal or human body.

  本发明涉及在蛋白激酶依赖性疾病的治疗中使用二芳基脲衍生物或用于制造用于治疗该类疾病的药物组合物，二芳基脲衍生物在治疗该类疾病中的使用方法，包含二芳基脲衍生物的制备用于治疗该类疾病的制药制剂，用于治疗该类疾病的二芳基脲衍生物，新型的二芳基脲衍生物，包含这些新型二芳基脲衍生物的制药制剂，制造这些新型二芳基脲衍生物的方法，上述新型二芳基脲衍生物的使用或使用方法，以及/或这些新型二芳基脲衍生物用于治疗动物或人体。
• [EN] DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES<br/>[FR] DERIVES DE DIARYLE-UREE UTILISES POUR LE TRAITEMENT DES MALADIES DEPENDANT DES PROTEINES KINASES
  申请人：——

  公开号：WO2003099771A3

  公开（公告）日：2004-04-01
• DIARYL UREA DERIVATIVES USEFUL FOR THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES
  申请人：Novartis AG

  公开号：EP1511730A2

  公开（公告）日：2005-03-09
• COMPOSITIONS AND METHODS FOR TREATING CANCERS
  申请人：Cedars-Sinai Medical Center

  公开号：US20170121297A1

  公开（公告）日：2017-05-04

  The invention describes compounds that inhibit both HDAC and GSK3β (i.e., HDAC/GSK3β dual inhibitors). The invention further describes compositions containing these HDAC/GSK3β dual inhibitors, as well as methods and kits using these HDAC/GSK3β dual inhibitors to treat various medical conditions. The invention also provides methods and kits using a HDAC inhibitor and a GSK3β to treat various medical conditions, and compositions containing a HDAC inhibitor and a GSK3β. Medical conditions treatable with various embodiments of the invention include but are not limited to caners and tumors.
• US7652022B2
  申请人：——

  公开号：US7652022B2

  公开（公告）日：2010-01-26